Introduction
Breast cancer is the most common cancer in women, behind skin cancer, and remains the second leading cause of cancer-related mortality (1) . This aggressive tumor type is classified into four broad subtypes: estrogen receptor positive (ER+), progesterone receptor positive (PR+), HER2 positive (HER2+) and triple-negative breast cancer (TNBC) characterized by an absence of ER, PR and HER2 expression. Indeed, TNBC has one of the highest metastatic potentials of all the subtypes, which is tightly associated to the high degree of vascularity feeding the tumor, known as intratumor microvascular density (iMVD) (2) . In the absence of abundant cell surface receptors for targeted therapy, key intracellular molecular players that drive TNBC are being sought as druggable targets.
In an effort to study the drivers of TNBC aggressiveness, emerging evidence points to a role for cyclic AMP (cAMP), a key secondary messenger, in breast cancer progression (3) . cAMP is involved in several signaling pathways, including those responsible for the regulation of cell proliferation, differentiation and migration (4, 5) . cAMP can act through two signaling axes: the PKA-dependent and the PKA-independent (6) . Indeed, the effect of PKA-independent pathway modulation through exchange factor directly activated by cAMP (EPAC1) is a well-established mode of regulating the networks (7) . EPAC1 is a guanine nucleotide exchange factor, which is involved in activity of Ras family proteins, specifically Rap1 and Rap2 (7, 8) . Furthermore, EPAC1 is implicated in several biological functions such as cell survival, cell junction interactions, secretions, cell-cell adhesion, differentiation and cell migration (7) (8) (9) (10) . However, the role of EPAC1 in metastasis is yet to be resolved.
As an important driver of metastasis, new blood supply to the tumor via neo-angiogenesis is a fundamental biological process that cancer cells can hijack (10) . Cancer cell-secreted factors in the tumor microenvironment can cause induction of new blood vessels and tumor cell dissemination (11) (12) (13) . Since the spread of tumors at a distant secondary site necessarily requires the initiation of angiogenesis to sustain the tumor mass, anti-angiogenic therapy has been employed to target highly metastatic cancers such as TNBC (14) . Despite these advances, little progress has been made to thwart metastasis, pin-point drivers and 'lynch-pins' of angiogenesis, and target these pathways to improve survival.
In this study, we interrogated the role of EPAC1 on the angiogenic and metastatic potential of TNBC using an endothelial cell in vitro model. We hypothesized that EPAC1 contributes to several phenotypic alterations in tumor cells including migratory and invasive features, as well as angiogenic potential of the tumor microenvironment and vasculature via the secretome. To test this hypothesis, we used gene knockdown studies and interrogated the effect of tumor cell secretome on iMVD, in vitro. Using gene ontology, we report a cell signaling network between cAMP-modulated EPAC1 and secreted molecular proteins that regulate neo-vascularization, migration, locomotion and blood vessel development. We further demonstrate a potential role for cell adhesion and matrix proteins including Paxillin, MENA and tubulin. With the help of a primary human tumor explant platform, we determined that iMVD is dynamic under drug pressure, and associates to predicted clinical response to therapy. Together, these findings demonstrate that EPAC1 supports the microvascular density of aggressive breast cancers, as well as the angiogenic and metastatic properties within the tumor microenvironment, which may underpin response or resistance to therapy. 
Material and methods

Antibodies and reagents
Cell culture conditions
MDA-MB-231 cells were cultured in 25 cm 2 vented culture flasks in L-15 medium supplemented with 10% fetal bovine serum. Cells were passaged twice a week and media was changed before each experiment. HUVEC cells were grown and cultured as per guided by manufacturers.
In vitro gene transfection
MDA-MB-231 cells were grown in a six-well plate for 24 h before transfection. siEPAC1 and all-star negative control siRNA were used with Lipofectamine-2000 for transfection. Cells were washed thrice with OptiMem and incubated with transfection mix for 4 h. After 4 h, media was replaced with fresh complete L-15 media and cells were kept for 48 h without disturbance. Cells were harvested and lysed for the analysis of Protein expression through western blot.
Preparation of conditioned media (CM)
MDA-MB-231 cells were grown in a six-well plate overnight (O/N) and transfected with siEPAC1 and control siRNA as discussed in above section. Conditioned media (CM) was collected and stored immediately at −80°C and used further for other experiments. Conditioned media (4 ml) was concentrated to 200 µl using 3 kDa filter and 1× phosphate buffer saline (PBS) buffer. Firstly, 3 kDa filter was equilibrated with 1× PBS buffer by centrifugation (4000 rpm for 30 min) and then conditioned and unconditioned media were added along with 1× PBS buffer in separate filters in 1:3 ratio (1 ml sample and 3 ml 1× PBS buffer) and centrifuged (4000 rpm for 30 min.). Flow through were discarded and same procedure was repeated three times until all media were passed. Finally, media were concentrated to 200 µl. After concentrating both conditioned and unconditioned media protein amount was quantified by Bradford assay and approximately 200 µg equivalent of protein lysate was used for angiogenesis array experiment.
Western blot analysis
Transfected cells were analyzed for the expression of EPAC1 and other proteins. MDA-MB-231 cells were harvested and lysed with lysis buffer (0.5 % SDS, 50 mM Tris-HCl, 1 mM EDTA). Cell lysate were loaded at 20 μg/ well and separated by 10 and 12.5% SDS-PAGE for 3 h at 120 V. Gel was transferred on to the polyvinylidene difluoride (PVDF) membrane for 1.5 h and membrane was blocked with blocking buffer (5% skim milk in PBS with 0.1% Tween-20) for 1 h. Membrane was incubated with primary antibodies (material section) in PBST O/N at 4°C. Next day, membrane was washed with PBST and incubated with secondary antibodies. Membrane was imaged with Alpha Imager system (Protein Simple). Results were analyzed and intensities were calculated using ImageJ software (15) .
Immunofluorescence assay
To explore the effect of down regulation of EPAC1 on MDA-MB-231 cells, we performed cellular imaging. Cells were seeded on coverslips and 
In vitro invasion assay
Invasive phenotype of cancer cells were analyzed with the culture insert (Corning). Culture inserts were coated with Matrigel (50 µg/ml/well) and incubated overnight at 37°C in CO 2 incubator. Transfected MDA-MB-231 cells were trypsinized and seeded in a density of 2.5 × 10 5 cells/ml in 200 µl media on to the insert with incomplete L-15 medium. Lower chamber of insert was filled with L-15 media (10 % FBS). After 24 h, cells were washed with 1× PBS. Fixing and staining was performed with methanol and crystal violet, respectively. Images of the invaded cells were captured by Leica Microscope. A total of three random areas from each well were selected and the experiment was repeated in triplicates.
2D angiogenesis assay
Tumor-induced angiogenesis assay was performed with primary cells (HUVEC) 
3D co-culture assay
To investigate the angiogenic tube formation in a tumor microenvironment condition, we performed a 3D co-culture assay. Before starting the assay, we transfected MDA-MB-231 cells with siEPAC1 as mentioned in above sections and loaded with CFSE dye for 30 min in dark. HUVECs and MDA-MB-231 cells were trypsinized and 5000 cells/100 µl was inter mixed with 100 µl matrigel and incubated in dark in a chamber slide. A media change was given carefully after 50 min and cells were kept in incubator for 2 days while media was changed every alternate day. Images were captured by Leica microscope and angiogenic tube sprouting of HUVEC in culture with MDA-MB-231 was quantified manually.
Angiogenesis profile assay assessment
Tissue culture media (4 ml) of transfected MDA-MB-231 cells was collected and concentrated as mentioned above. Concentrated protein was quantified by Bradford assay and pour on to the membranes following manufacturer instructions. Approximately 200 µg equivalent of protein was taken for array experiment from both control and siEPAC1 transfected tissue culture media. Proteome profiling for angiogenic proteins was performed according to manufacturer's protocol. Results were analyzed using ImageJ software (15) . Angiogenic proteome profiling was done two times (biological duplicate).
Electric cell-substrate impedance sensing (ECIS)-based analysis
To analyze the effect of cancer cells on vascular permeability in primary cells, we performed ECIS assay. Electric Cell-substrate Impedance Sensing (Applied Biophysics) is a real-time analysis of cellular activities in culture system. It is an impedance-based system to check the morphological, migratory and vascular leakage properties of cultured cells (17) . HUVECs were plated on 8W10E microchips, pre-coated with gelatin. After 24 h, CM from siEPAC1 transfected cells along with control transfected cells were poured in to the wells. HUVECs without any CM were used as control for treated cells. In one well, 8-O-ME cAMP treatment was given for 20 min and after removal of 8-O-ME cAMP, CM of EPAC1 transfected cells was used. Effect on changes in electric impedance of the monolayer was monitored at every 10 s. Endothelial cell permeability in the in vitro mimic condition of cancer metastasis was observed until 48 h and analyzed by ECIS software.
Human explant studies
Anonymous human TNBC tissues were assessed by CANscript TM using fresh specimen. All samples were taken from patients refractory to taxane-containing regimens and varying stages of disease were obtained from Mitra Biotech collected under IRB approval from HCG Bangalore Institute of Oncology with due consent. Fresh tumor tissues were collected immediately after surgical resection. The tumor samples were transported to the laboratory at 4°C, in appropriate transport buffer within 60 min post-resection, for ex vivo studies and molecular and pathological evaluation. Tissues were cut into thin sections and cultured in tissue culture plates using optimized conditions with matrix proteins that match the tumor indication and grade. Tumors were treated with a taxane (docetaxel) at clinical max concentration (Cmax) for 72 h. DMSO was used as a vehicle control. After treatment, tumor cell viability was measured. Immunohistochemistry (IHC) was performed as described in methods. As a quality control measure, each tumor tissue contains at least 20% tumor content, which is evaluated by clinical pathologists. Predicting response to therapy was performed using a clinically trained algorithm that was described previously (18) .
Immunohistochemical analysis
Changes in CD34+ was determined prior to and after drug treatment evaluated by IHC using specific antibodies. 
Results
Downregulation of EPAC1 in TNBC cells reduces angiogenesis in HUVEC culture models, in vitro
We first asked whether TNBC-related EPAC1 contributes to angiogenesis. To address this, we employed an in vitro model that harnesses human vascular endothelial cells (HUVEC) grown in culture with media that was pre-conditioned overnight by the 
Downregulation of tumor cell EPAC1 reduces invasion and angiogenic sprouting in vitro
Next, we wanted to interrogate the role of EPAC1 as it confers angiogenic properties in a tumor-endothelial cell co-culture experiment. To do this, we employed a 3-D co-culture assay, which was performed with HUVECs in the presence of siEPAC1-and control siRNA-transfected MDA-MB-231 cells that are pre-labeled with a fluorescent dye (e.g. CSFE). Incubating cells together, we determined that fewer endothelial cell sprouting events occurred in HUVEC cells (CSFE neg ) when cultured with siEPAC1-transfected MDA-MB-231 cells with respect to control cells ( Figure 2A , *P < 0.05, N = 3). To support these findings, we analyzed tumor cell invasion using a trans-well assay (see Methods for details). While our observations were consistent with previous evidence that TNBC are highly invasive, we determined, based on the number of invading MDA-MB-231 through micropores, EPAC1 knockdown led to diminished invasion compared to wild-type (siRNA control) conditions (Figure 2B, *P < 0.05 N = 3). This finding suggests that EPAC1 may play a critical role in both neovascularization (via the secretome) and invasive properties of tumor cells into the vasculature, two features that are key in driving metastasis.
Loss of EPAC1 leads to dysregulation of pro-and anti-angiogenic proteins in the tumor secretome
Based on the evidence above, we suspected extracellular signals derived from tumor cells mediate the angiogenic behavior we observed in HUVEC. Therefore, we interrogated the secretome of tumor cells treated with siEPAC1 or a scrambled control. We employed a proteome array to profile angiogenic proteins from CM of siEPAC1 and control siControl MDA-MB-231 cells. As shown in the waterfall and volcano plots, we identified numerous statistically significantly downregulated proteins in the TNBC secretome after silencing EPAC1 including fibroblast growth factor family members (FGF-4 and FGF-a) and transforming growth factor (TGF) family member TGFb and complement protein, amphiregulin ( Figure 3A-C) . Furthermore, we identified a small number of proteins were increased (most notably SERPINE1 and Thrombospondin-1) (Figure 3B and C) . To understand the relationship between the proteins dysregulated in the siEPAC1 TNBC secretome, we performed gene ontology (GO) analysis. Based on a statistically significant false discovery rate (FDR < 0.001), we determined that downregulation of EPAC1 leads to an increase in proteins that are involved in negative regulation of adhesion, blood vessel morphogenesis and angiogenesis ( Figure 3C ). Proteins that positively regulate cell migration and locomotion were found to be significantly downregulated after silencing EPAC1 ( Figure 3D , *P < 0.05).
EPAC1 downregulation affects cellular adhesion, blood vessel development and intracellular network scaffolding properties
Next, we sought to interrogate proteins that are associated with the intracellular scaffold network, which may drive cell open source software, false discovery rate was set P < 0.001. Proteome array was performed in duplicate and biological replicate on two independent occasions (N = 4). migration and locomotion. Using confocal microscopy, we profiled focal adhesion proteins including MENA and Paxillin, which are associated with malignant migratory features (20, 21) . MENA protein spots were found to be localized at the periphery in siRNA control cells, which are diminished when EPAC1 is downregulated ( Figure 4A ). This evidence was confirmed by western blot analysis ( Figure 4B ). Confocal analysis also indicated the dysregulation of the cytoskeleton marker tubulin. ImageJ analysis of tubulin was done to confirm the difference in control and siEPAC1 treated cells (*P < 0.05, N > 3 replicates from multiple fields) ( Figure 4A; Supplementary Figure 1A , available at Carcinogenesis Online), which was confirmed by western blot ( Figure 4B; Supplementary Figure 1B , available at Carcinogenesis Online). Furthermore, we identified a diminished intensity and lower incidence of Paxillin observed by confocal imaging ( Figure 4C; Supplementary Figure 1C , available at Carcinogenesis Online), which were also confirmed by western blot analysis ( Figure 4D; Supplementary Figure 1D , available at Carcinogenesis Online).
Role of EPAC1 and the cytoskeleton in HUVEC in vascular permeability
In order to study dynamic changes in cell motility and locomotion, we interrogated the permeability of endothelial cells, which infers changes to the intracellular cytoskeleton and can be performed using ECIS (17) . We plated endothelial cells (HUVEC) on an ECIS microchip following standard protocol to interrogate metastasis (22) . The cells were allowed to spread and form junctions and cell-cell contact on the chip. Conditioned media of control siRNA transfected MDA-MB-231 cells changed the junctional properties and increased the vascular permeability of the endothelial cell monolayer ( Figure 5 , magenta trace). We activated signaling by addition of 8-pCPT-2-O-Me-cAMP-AM and found tightening of endothelial cell monolayer which is evidenced by increased normalized resistance ( Figure 5 , red trace). Interestingly, silencing EPAC1 modulated this increased permeabilization ( Figure 5 , blue trace).
Ex vivo tumor culture associates microvascular density with response to therapy
To this point, we have developed comprehensive evidence to support EPAC1 as a putative 'lynch-pin' for microvascular density, invasion and angiogenesis, which contribute to metastatic features of the tumor-endothelium. To provide a clinical translation of iMVD in the context of breast cancer treatment, we first studied the role of microvascular density in primary human tumor tissue. Recent evidence indicates that iMVD may be prognostic following treatment with conventional anticancer agents, including cytotoxic chemotherapy (23) . Therefore, we employed a recently-described human cancer explant assay that closely represents clinical response and resistance to therapy (CANscript TM ) (18) . Explants were generated from fresh tumor biopsy isolated from TNBC and hormone receptor positive patients, and cultured ex vivo on matched tumor matrix proteins supplemented with autologous patient plasma. The explants were treated with cytotoxic chemotherapies at clinically reported C max doses for 72 h, and evaluated for: (1) predicted response to therapy using a clinically trained algorithm (i.e. M-Score) (18) , and (2) CD34 + neovasculature nodes by IHC (24) (Figure 6A and B) . Primarily, we confirmed a high incidence of iMVD in TNBC tissue compared to hormone receptor positive samples ( Figure 6C and D *P < 0.05). By quantifying incidence of CD34 + expression from IHC, our preliminary evidence suggests that response to therapy may be linked to baseline expression of CD34+ vascular nodes ( Figure 6E ). Indeed, we determined that a reduction in CD34+ nodes associates to poor response to therapy, which was predicted by the clinically trained algorithm ( Figure 6E ). 
Discussion
Neovascularization and angiogenesis are key features of metastasis and cancer-related mortality. Our recent evidence that EPAC1 associates to tumor dissemination lead us to study its effect on angiogenic and invasive properties. To do this, we employed molecular techniques that allow us to modulate expression of EPAC1 and interrogate phenotypic effects using in vitro models of TNBC. Using a human breast cancer ex vivo assay, we also provide evidence that dynamic alterations to iMVD and neo-vascularization under drug pressure, determined using CD34
+ expression and a quantitative clinical pathology approach, may provide clues to therapy response and failure. Together, these findings provide evidence that link biomarkers of metastasis with iMVD and therapy failure, features that may be supported by a key 'lynch-pin', EPAC1 (see proposed schematic, Supplementary Figure 2 , available at Carcinogenesis Online).
Vascular mimicry is a process in which cancer cells acquire endothelial cell-like properties to aid metastatic potential (25) . Interestingly, serine proteases (i.e. SERPIN family of proteins) are known to program cancer cells for vascular mimicry (26) . Indeed, our proteome profiling analysis identified a link between SERPIN (E1) and EPAC1. Although our profile did not provide a statistical link between SERPINE1 overexpression, when we combined that evidence with our identification of thrombospondin 1, we determined there is a statistically significant network of proteins that negatively regulate migration and angiogenesis. Indeed, these features are highly associated with high iMVD and breast cancer metastasis (27) . Future examination of SERPINE1 may elucidate a signaling network that underpins aggressive features of angiogenesis, and therefore a potential druggable target.
Interestingly, evidence in other tumor types, such as pancreatic ductal adenocarcinoma, suggests that EPAC1 is involved in migration and invasion (4) . In fact, conditioned medium of melanoma cells with high expression of EPAC1 causes increased migration of HUVEC through Fibroblast growth factors (FGF2) (28) . Similarly, our study has provided preliminary evidence that FGF may play a role, in-concert with other proteins, to drive EPAC1-mediated angiogenesis and metastatic phenotypes. Indeed, several FGF family members are modulated in EPAC1-diminished MDA-MB-231 cells, which classifies some of the earliest angiogenic-factors described in breast cancer and is also involved in metastasis progression (29) . In addition to these growth factors, we noted statistically significantly downregulated proteins in siRNA EPAC1 treated MDA-MB-231 cells including IGFBP3, Activin-A and Amphiregulin, which have been loosely associated with poor prognosis for metastatic cancer (30) . We speculate that these growth factors may harmonize to provide a substrate for angiogenic potential, which is dysregulated in TNBC versus luminal breast cancers. Further examination of these associations may be warranted. Excitingly, our preliminary evidence from ex-vivo culture suggests a link between CD34+ incidence and neovascularization (angiogenesis), which may predispose response to therapy, thus bridging prognosis of aggressive cancers, such as TNBC, with iMVD and metastasis. Indeed, previous studies have shown that iMVD can be reliably measured by quantifying the occurrence of CD34 marker, and that MVD can be used to evaluate the rate of neoangiogenesis in breast cancer (31) . Our evidence that CD34 is dynamically altered under drug pressure, and is potentially tied to clinical response, is a key finding that may link the expression of EPAC1. However, more work needs to be done in order to pinpoint this relationship. These findings have now driven us to explore how microvascular density and other precursor biomarkers of angiogenesis may contribute to treatment response or failure. Such an ex vivo assay may help elucidate the role of antiangiogenic drugs, such as bevacizumab, in breast cancer and other tumor indications.
In addition, our study provides a comprehensive look into the mechanisms of EPAC1-related tumor metastasis. Key protein networks that underpin this effect may provide clues and new druggable targets. With the use of CANscript and tumor modeling ex vivo, we are able to study how the entire tumor ecosystem, biomarkers of neovascularization and dynamic changes to the microenvironment contribute to early dissemination of tumor cells and treatment response. Together with angiogenic molecular profiling, we anticipate a concerted effort to target these proteins could overcome the challenges associated with metastatic breast cancer.
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Supplementary material can be found at Carcinogenesis online.
